NanoViricides Inc. (NNVC)

[bloomvest]

Classic PR from 2006."We now have three nanoviricides(TM), all effective against H5N1, entering further detailed studies with the goal of filing INDs," he added, explaining, "the data were fully consistent with our design expectations." Thus, AviFluCide-I(TM) is designed to be specific to H5N1, and FluCide-I(TM) is designed to work against all influenzas, whereas FluCide-HP(TM) is designed to work against the entire highly pathogenic influenza subgroup that poses continuously re-emerging and changing pandemics threats.

Highlighting new information gleaned from H5N1 preclinical studies recently completed in Vietnam, Dr. Diwan showed that many nanoviricide(TM) candidates were effective at as low as 5-nanomolar concentration levels in cell culture experiments. Typically, an early developmental drug that proves effective at concentrations less than 500 nanomolars is considered a strong candidate for FDA approval as an "Investigational New Drug (IND)" applicant.